Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label TAS-115 monotherapy in castration-resistant prostate cancer
jRCT2080223393Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pamufetinib in prostate cancer (PCa), sponsored by Taiho Pharmaceutical Co., Ltd. Started Nov 2016; status: completed.
02
Drugs
pamufetinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080223393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223393.